Introduction Treatment options in the second-line extensive-stage SCLC (ED-SCLC) setting
are limited. The PASSION study (ClinicalTrials. gov identifier: NCT03417895) was a phase 2 …

Abstract Introduction In CameL phase 3 study (ClinicalTrials. gov: NCT03134872), addition
of camrelizumab to first-line chemotherapy significantly improved the progression-free …

Introduction This open-label, phase 1–2 study evaluated the safety and efficacy of
rovalpituzumab tesirine (Rova-T), an antibody-drug conjugate targeting DLL3, plus immune …

Introduction Pembrolizumab has shown clinical benefit in patients with previously treated
recurrent or metastatic SCLC in the phase 1b multicohort study KEYNOTE-028 …

Abstract Introduction We assessed the Aurora A kinase inhibitor, alisertib, plus paclitaxel
(henceforth referred to as alisertib/paclitaxel) as second-line treatment for SCLC. Methods In …

Objectives Our aim was to evaluate the safety and efficacy of ipilimumab combined with
standard first-line chemotherapy for patients with extensive-stage SCLC. Methods Patients …

Purpose Despite high tumor mutationburden, immune checkpoint blockade has limited
efficacy in SCLC. We hypothesized that poly (ADP-ribose) polymerase inhibition could …

Introduction Small cell lung cancer (SCLC) is an aggressive malignancy that although
initially sensitive to chemo-and radiation therapy, inevitably relapses resulting in poor …

Abstract Introduction ZL-2306-005 is a randomized, double-blind, multicenter phase 3 study
evaluating the efficacy and safety of niraparib, a poly (adenosine diphosphate-ribose) …

Introduction For patients with recurrent SCLC, topotecan remains the only approved second-
line treatment, and the outcomes are poor. CheckMate 032 is a phase 1/2, multicenter, open …